Study Comparing MORAb-202 with Chemotherapy for Women with Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Inclusion Criteria

• Women diagnosed with high-grade serous ovarian, primary peritoneal, or fallopian tube cancer.
• Cancer that has not responded to platinum-based treatments, defined as:
  • If only one round of platinum treatment was given, the cancer returned between 1 and 6 months after the last dose.
  • If two or three rounds of platinum treatment were given, the cancer returned within 6 months after the last dose.
• Have had at least one but no more than three previous treatments, and single-agent therapy is suitable as the next step.
• Cancer has progressed with at least one measurable tumor after the most recent treatment.
• Must provide a tissue sample for FRα testing before starting the study.
• Must be in good general health with an ECOG performance status of 0 or 1.

Exclusion Criteria

• Have certain types of ovarian cancer, such as clear cell, mucinous, endometrioid, or sarcomatous, or mixed tumors with these types.
• Cancer that did not respond to the first round of platinum treatment.
• Have lung function issues, such as low FEV1, FVC, or DLCO.
• Have or had lung inflammation (ILD/pneumonitis) or are suspected to have it.
• Have significant fluid buildup in the body that needs frequent draining.
• Have organ dysfunction or significant abnormalities in physical exams or lab tests.
• Have severe allergies to monoclonal antibodies, eribulin, or corticosteroids, or any ingredients in the study drugs.
• Have allergies or contraindications to the chemotherapy chosen for the study.